Human Immunodeficiency Virus Reverse Transcriptase

The Reverse Transcriptase (RT) of Human Immunodeficiency Virus Type 1 (HIV-1) arguably ranks amongst one of the most extensively studied retroviral enzymes. Heterologous expression and purification of HIV-1 RT in the early eighties, approval of the first nucleoside analogue RT inhibitor (NRTI) in 19...

Full description

Corporate Author: SpringerLink (Online service)
Other Authors: LeGrice, Stuart. (Editor, http://id.loc.gov/vocabulary/relators/edt), Gotte, Matthias. (Editor, http://id.loc.gov/vocabulary/relators/edt)
Language:English
Published: New York, NY : Springer New York : Imprint: Springer, 2013.
Edition:1st ed. 2013.
Subjects:
Online Access:https://doi.org/10.1007/978-1-4614-7291-9
LEADER 04305nam a22004935i 4500
001 978-1-4614-7291-9
003 DE-He213
005 20210617022240.0
007 cr nn 008mamaa
008 130722s2013 xxu| s |||| 0|eng d
020 |a 9781461472919  |9 978-1-4614-7291-9 
024 7 |a 10.1007/978-1-4614-7291-9  |2 doi 
050 4 |a QR355-502 
072 7 |a MMFM  |2 bicssc 
072 7 |a MED052000  |2 bisacsh 
072 7 |a MKFM  |2 thema 
082 0 4 |a 616.9101  |2 23 
245 1 0 |a Human Immunodeficiency Virus Reverse Transcriptase  |h [electronic resource] /  |c edited by Stuart LeGrice, Matthias Gotte. 
250 |a 1st ed. 2013. 
264 1 |a New York, NY :  |b Springer New York :  |b Imprint: Springer,  |c 2013. 
300 |a X, 361 p.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
520 |a The Reverse Transcriptase (RT) of Human Immunodeficiency Virus Type 1 (HIV-1) arguably ranks amongst one of the most extensively studied retroviral enzymes. Heterologous expression and purification of HIV-1 RT in the early eighties, approval of the first nucleoside analogue RT inhibitor (NRTI) in 1987, discovery of resistance to RT inhibitors, approval of the first non-nucleoside analogue RT inhibitor (NNRTI) in 1996 and the various crystal structures of RT with and without bound substrate(s) and/or inhibitors represent only a few of the important milestones that describe the a bench-to-bedside success in the continuing effort to combat HIV-1 infection and its consequences. Nucleoside and nonnucleoside RT inhibitors remain important components in frequently used drug regimens to treat the infection. RT inhibitors also play important roles in recently validated strategies to prevent transmission of the virus. The relevance of HIV-1 RT as a drug target has simultaneously triggered interest in basic research studies aimed at providing a more detailed understanding of interactions between proteins, nucleic acids, and small molecule ligands in general terms. In light of the ever-growing knowledge on structure and function of HIV-1 RT, this enzyme serves as a valuable “model system” in efforts to develop novel experimental tools and to explain biochemical processes. This monograph is designed to provide an overview of important aspects in past and current HIV-1 RT research, with focus on mechanistic aspects and translation of knowledge into drug discovery and development. The first section includes chapters with emphasis placed on the coordination of the RT-associated DNA polymerase and ribonuclease H (RNase H) activities. The second covers mechanisms of action and future perspectives associated with NRTIs and NNRTIs, while the third section includes chapters focusing on novel strategies to target the RT enzyme. Chapters of the final part are intended to discuss mechanisms involved in HIV variability and the development of drug resistance. We hope that these contributions will stimulate interest, and encourage research aimed at the development of novel RT inhibitors. The lack of bona fide RNase H inhibitors with potent antiviral activity provides an example for challenges and opportunities in the field. 
650 0 |a Virology. 
650 0 |a Infectious diseases. 
650 0 |a Immunology. 
650 1 4 |a Virology.  |0 https://scigraph.springernature.com/ontologies/product-market-codes/B22003 
650 2 4 |a Infectious Diseases.  |0 https://scigraph.springernature.com/ontologies/product-market-codes/H33096 
650 2 4 |a Immunology.  |0 https://scigraph.springernature.com/ontologies/product-market-codes/B14000 
700 1 |a LeGrice, Stuart.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
700 1 |a Gotte, Matthias.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer Nature eBook 
776 0 8 |i Printed edition:  |z 9781489999535 
776 0 8 |i Printed edition:  |z 9781461472926 
776 0 8 |i Printed edition:  |z 9781461472902 
856 4 0 |u https://doi.org/10.1007/978-1-4614-7291-9 
912 |a ZDB-2-SBL 
912 |a ZDB-2-SXB 
950 |a Biomedical and Life Sciences (SpringerNature-11642) 
950 |a Biomedical and Life Sciences (R0) (SpringerNature-43708)